Quizartinib is an FLT3 inhibitor. It’s used to treat people with relapsed or refractory AML who have FLT3-internal tandem duplication (ITD) mutations. The way it works is by stopping FLT3 signaling, which is a big deal in how AML happens in people with FLT3 mutations.
You can get the medicine in two strengths: 17.7 mg and 26.5 mg tablets. You start with 53 mg per day, and you’ll slowly work your way up. The tablets come in bottles with 28 in each.
You gradually up your dose to get to the right amount. It’s been effective in cutting down FLT3 signaling and possibly helping patients in clinical studies.
Reviews
There are no reviews yet.